OBJECTIVE: To examine trends in tuberculosis incidence rates in France during the combination antiretroviral therapy (cART) period. METHODS: From the French Hospital Database on HIV, we selected 72 580 patients (including 14 491 migrants) with no history of tuberculosis, followed between 1 January 1997 and 31 December 2008. We then examined incidence rates of tuberculosis and its risk factors. RESULTS: A total of 2625 patients were diagnosed with tuberculosis either at enrollment (N = 932) or during follow-up (N = 1693). During follow-up, the incidence rate of tuberculosis was 0.40/100 patient-years overall, 0.20 among non-migrants and 1.03 among migrants. Adjusted risk of tuberculosis was 2.01 [95% confidence interval (CI) 1.79-2.26] times higher in migrants than in non-migrants. The adjusted incidence rate of tuberculosis significantly increased in both migrants and non-migrants after 2000-2001, with adjusted risks of 2.50 (95% CI 1.54-4.06) and 1.85 (95% CI 1.27-2.69) in 2008 compared with that in 1997, respectively. Other factors independently associated with a higher incidence of tuberculosis were medical follow-up less than or equal to 6 months, no previous antiretroviral therapy, lower CD4 cell count and higher viral load. Non-migrant patients belonging to HIV-transmission groups other than homosexual men, residing in the Paris area or in French West Indies or with AIDS status were at a supplementary risk. CONCLUSION: The incidence of tuberculosis is increasing among both migrant and non-migrant HIV-infected patients in France. This is partly because sub-Saharan African migrants represent an increasing fraction of the HIV-infected population in France and also because of late access to care. Co-prescribing tuberculosis preventive therapy with cART might benefit selected patients, such as migrants and patients with late access to care.
OBJECTIVE: To examine trends in tuberculosis incidence rates in France during the combination antiretroviral therapy (cART) period. METHODS: From the French Hospital Database on HIV, we selected 72 580 patients (including 14 491 migrants) with no history of tuberculosis, followed between 1 January 1997 and 31 December 2008. We then examined incidence rates of tuberculosis and its risk factors. RESULTS: A total of 2625 patients were diagnosed with tuberculosis either at enrollment (N = 932) or during follow-up (N = 1693). During follow-up, the incidence rate of tuberculosis was 0.40/100 patient-years overall, 0.20 among non-migrants and 1.03 among migrants. Adjusted risk of tuberculosis was 2.01 [95% confidence interval (CI) 1.79-2.26] times higher in migrants than in non-migrants. The adjusted incidence rate of tuberculosis significantly increased in both migrants and non-migrants after 2000-2001, with adjusted risks of 2.50 (95% CI 1.54-4.06) and 1.85 (95% CI 1.27-2.69) in 2008 compared with that in 1997, respectively. Other factors independently associated with a higher incidence of tuberculosis were medical follow-up less than or equal to 6 months, no previous antiretroviral therapy, lower CD4 cell count and higher viral load. Non-migrant patients belonging to HIV-transmission groups other than homosexual men, residing in the Paris area or in French West Indies or with AIDS status were at a supplementary risk. CONCLUSION: The incidence of tuberculosis is increasing among both migrant and non-migrant HIV-infectedpatients in France. This is partly because sub-Saharan African migrants represent an increasing fraction of the HIV-infected population in France and also because of late access to care. Co-prescribing tuberculosis preventive therapy with cART might benefit selected patients, such as migrants and patients with late access to care.
Authors: David Stucki; Marie Ballif; Matthias Egger; Hansjakob Furrer; Ekkehardt Altpeter; Manuel Battegay; Sara Droz; Thomas Bruderer; Mireia Coscolla; Sonia Borrell; Kathrin Zürcher; Jean-Paul Janssens; Alexandra Calmy; Jesica Mazza Stalder; Katia Jaton; Hans L Rieder; Gaby E Pfyffer; Hans H Siegrist; Matthias Hoffmann; Jan Fehr; Marisa Dolina; Reno Frei; Jacques Schrenzel; Erik C Böttger; Sebastien Gagneux; Lukas Fenner Journal: J Clin Microbiol Date: 2016-05-18 Impact factor: 5.948
Authors: Lukas Fenner; Sebastien Gagneux; Peter Helbling; Manuel Battegay; Hans L Rieder; Gaby E Pfyffer; Marcel Zwahlen; Hansjakob Furrer; Hans H Siegrist; Jan Fehr; Marisa Dolina; Alexandra Calmy; David Stucki; Katia Jaton; Jean-Paul Janssens; Jesica Mazza Stalder; Thomas Bodmer; Beatrice Ninet; Erik C Böttger; Matthias Egger Journal: J Clin Microbiol Date: 2011-11-23 Impact factor: 5.948
Authors: Julia del Amo; Santiago Moreno; Heiner C Bucher; Hansjakob Furrer; Roger Logan; Jonathan Sterne; Santiago Pérez-Hoyos; Inma Jarrín; Andrew Phillips; Sara Lodi; Ard van Sighem; Wolf de Wolf; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; José M Miró; Elena Ferrer; Laurence Meyer; Rémonie Seng; Giota Toulomi; Panagiotis Gargalianos; Dominique Costagliola; Sophie Abgrall; Miguel A Hernán Journal: Clin Infect Dis Date: 2012-03-28 Impact factor: 9.079
Authors: Bryan E Shepherd; Cathy A Jenkins; Deidra D Parrish; Tracy R Glass; Angela Cescon; Angels Masabeu; Genevieve Chene; Frank de Wolf; Heidi M Crane; Inma Jarrin; John Gill; Julia del Amo; Sophie Abgrall; Pavel Khaykin; Clara Lehmann; Suzanne M Ingle; Margaret T May; Jonathan A C Sterne; Timothy R Sterling Journal: AIDS Date: 2013-05-15 Impact factor: 4.177
Authors: Laure-Amélie de Monteynard; Rosemary Dray-Spira; Pierre de Truchis; Sophie Grabar; Odile Launay; Jean-Luc Meynard; Marie-Aude Khuong-Josses; Jacques Gilquin; David Rey; Anne Simon; Juliette Pavie; Aba Mahamat; Sophie Matheron; Dominique Costagliola; Sophie Abgrall Journal: PLoS One Date: 2015-03-03 Impact factor: 3.240